Sector News

J&J buying Vogue Int’l for about $3.3B

June 3, 2016
Life sciences

Johnson & Johnson is buying hair care products maker Vogue International for about $3.3 billion.

Privately-held Vogue also sells other personal care products.

The acquisition will give Johnson & Johnson the OGX collection of shampoos, conditioners, treatments, styling products, body care and bath products, the FX hair styling product line and the Proganix and Maui Moisture hair care lines.

Vogue’s hair care products are sold in the U.S. and 38 other countries.

Johnson & Johnson, based in New Brunswick, N.J., has brands including Neutrogena and Band-Aid.

The deal is expected to close in the third quarter.

Johnson & Johnson said that the transaction isn’t expected to impact its previously announced full-year sales and earnings forecasts.

J&J shares rose 47 cents to $113.25 in morning trading Thursday. Its shares are up more than 13 percent over the past year.

Source: Associated Press via Salt Lake Tribune

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach